Feature | August 28, 2006| Kim Phelan

Especially, says HRS, when ICD malfunction is involved

The day our May issue went to press, April 26, the Heart Rhythm Society held a telebriefing for the media to announce release of its draft policy recommendations for pacemaker and ICD performance. Final guidelines are expected to be published in the October issue of Heart Rhythm Journal, but I believe highlighting some of Dr. Anne Curtis’ remarks is of immense value to all cardiology practitioners.
Emphasis on clear communication practices is among the standout messages I take away from the recommendations — perhaps because I’ve always preferred clarity to clouding, straight talk rather than empty loquacity.
The need for the Society to take a stand about ICD and pacemaker performance and malfunction mitigation is obvious in view of product recalls last year following some serious adverse patient events, including deaths.
“While the life-saving benefits of pacemakers and ICDs has been confirmed by numerous clinical trials, recent events have raised questions about the effectiveness of the current systems and processes used for postmarket surveillance and analysis of these cardiac devices,” said Dr. Curtis. “Industry communications to physicians and patients about the performance of these devices have also been called into question.”
She stated that physicians are not currently, systematically involved in determining if and when a device safety concern exists or in the response to a safety concern. Of all the document’s recommendations, Dr. Curtis noted two as among the most significant:
(1.) “We suggest that manufacturers establish independent, standing committees of outside experts to analyze device performance reports and to recommend appropriate action.”
(2.) “We recommend the FDA establish standing postmarketing advisory committees to analyze data on device performance and to suggest actions to address device malfunctions.”

Simple, Straight and Standardized
When so much is at stake, communication related to device malfunction should not be clouded with complex and inconsistent terminology, the Society asserts. Device manufacturers and the FDA are therefore urged to use identical terminology when classifying device malfunction.
Simple language should be used by the FDA in communicating important malfunction information, stated Dr. Curtis. She also emphasized how the present absence of a standardized reporting format and of a standard mechanism for FDA classification of all advisories creates confusion, the first hindering physician and patient understanding of key clinical issues at stake and the second potentially leading to over or under emphasis on any particular advisory issue. Manufacturers must contribute to the solution, she indicated.
“In addition to the physician advisory notification letters, we suggest that manufacturers use a standardized physician device advisory notification format for all industry advisories to physicians regarding potential device malfunctions.”

What’s Your Story?
In the next issue of Diagnostic & Invasive Cardiology, we will cover the prevention and treatment of heart failure. If you are a physician who is involved in the advances of heart failure therapy, please call or email me during the month of July. We would like to hear about your work and share your story with your peers in this DAIC-exclusive feature.
Meanwhile, thanks for reading this issue!

Related Content

Boston Scientific, FDA, ImageReady MR-Conditional Pacing System
Technology | EP Lab| April 28, 2016
Boston Scientific has received U.S. Food and Drug Administration (FDA) approval for a suite of products deemed safe for...
Micra Transcatheter Pacing System (TPS), TPS, smallest pacemaker
Technology | Pacemakers| April 11, 2016
April 11, 2016 - The U.S.
ICDs, implantable cardioverter defibrillators, end-of-life deactivation, shocks, ACC 2016
News | Implantable Cardioverter Defibrillators (ICD)| April 03, 2016
Many patients who have an implantable cardioverter defibrillator (ICD) are unaware the device can be deactivated to...
St. Jude Medical, CE Mark and launch, quadripolar pacing leads
News | Leads Implantable Devices| March 29, 2016
St. Jude Medical Inc. announced CE Mark approval and launch of three new Quartet left ventricular (LV) leads, offering...
Medtronic, CE Mark, MRI compatibility, CRT-Ds, pacemakers, ICDs

Amplia MRI Quad CRT-D SureScan image courtesy of Medtronic

News | Cardiac Resynchronization Therapy Devices (CRT)| March 17, 2016
Medtronic plc announced that it received CE (Conformité Européenne) Mark for the first and only cardiac...
St. Jude Medical, Nanostim leadless pacemaker, CE Mark Europe, MRI compatibility
News | Pacemakers| March 10, 2016
St. Jude Medical Inc. announced CE Mark approval for magnetic resonance (MR) conditional labeling for 1.5 T scans for...
Boston Scientific, Acuity X4 quadripolar left ventricular leads, FDA approval, ENABLE MRI study
Technology | Leads Implantable Devices| March 04, 2016
March 4, 2016 — Boston Scientific has received U.S.
Biotronik, Itrevia 7 HF-T CRT-D device, Japan approval, full-body MRI scanning
News | Cardiac Resynchronization Therapy Devices (CRT)| February 25, 2016
Biotronik announced that its Itrevia 7 HF-T cardiac resynchronization therapy defibrillator (CRT-D) has now been...
St. Jude Medical, FDA clearance, MultiPoint Pacing technology, CRT-D, CRT-P
News | Leads Implantable Devices| February 17, 2016
St. Jude Medical Inc. announced U.S. Food and Drug Administration (FDA) approval of the first-to-market MultiPoint ...
Biotronik, CE approval, Ilivia ICDs and CRT-Ds, ProMRI, MRI AutoDetect
News | Implantable Cardioverter Defibrillators (ICD)| February 03, 2016
Biotronik announced CE approval for its new Ilivia implantable cardioverter defibrillators (ICDs) and cardiac...
Overlay Init